Search research articles
Contact Us
Filters
Showing results (11-20 of 42) with videos related to
Page
of 5
Sort By:
Community Mental Health Journal
|
September 20, 2025
Facebook as a Strategy To Deliver a Peer Navigation Intervention for Recently Incarcerated Women with Opioid Use Disorder: A Mixed Methods Descriptive Profile
Martha Tillson, Jaxin Annett, Marguerite A Webster, et al.
The Journal of Infectious Diseases
|
July 16, 2024
Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial
Christine Lacabaratz, Mélany Durand, Aurélie Wiedemann, et al.
Global Health Action
|
October 19, 2020
Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda
Jonathan Kitonsa, Abu-Baker Ggayi, Zacchaeus Anywaine, et al.
Plos Neglected Tropical Diseases
|
April 11, 2024
Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
Houreratou Barry, Edouard Lhomme, Mathieu Surénaud, et al.
The Journal of Infectious Diseases
|
February 24, 2019
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
Zacchaeus Anywaine, Hilary Whitworth, Pontiano Kaleebu, et al.
Human Vaccines & Immunotherapeutics
|
August 14, 2025
Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy
Gloria Aguilar, Gabriela Tapia-Calle, Cynthia Robinson, et al.
The Journal of Infectious Diseases
|
July 1, 2022
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign
Julien Nyombayire, Rosine Ingabire, Ben Magod, et al.
Trials
|
June 20, 2022
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial
Etienne Karita, Julien Nyombayire, Rosine Ingabire, et al.
The Lancet. Infectious Diseases
|
March 29, 2024
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial
Ynke Larivière, Trésor Zola Matuvanga, Bernard Isekah Osang'ir, et al.
The Journal of Infectious Diseases
|
September 6, 2023
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo
Ynke Larivière, Irene Garcia-Fogeda, Trésor Zola Matuvanga, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 42) with videos related to
Sort By:
Page
of 5
Community Mental Health Journal
|
September 20, 2025
Facebook as a Strategy To Deliver a Peer Navigation Intervention for Recently Incarcerated Women with Opioid Use Disorder: A Mixed Methods Descriptive Profile
Martha Tillson, Jaxin Annett, Marguerite A Webster, et al.
The Journal of Infectious Diseases
|
July 16, 2024
Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial
Christine Lacabaratz, Mélany Durand, Aurélie Wiedemann, et al.
Global Health Action
|
October 19, 2020
Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda
Jonathan Kitonsa, Abu-Baker Ggayi, Zacchaeus Anywaine, et al.
Plos Neglected Tropical Diseases
|
April 11, 2024
Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
Houreratou Barry, Edouard Lhomme, Mathieu Surénaud, et al.
The Journal of Infectious Diseases
|
February 24, 2019
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
Zacchaeus Anywaine, Hilary Whitworth, Pontiano Kaleebu, et al.
Human Vaccines & Immunotherapeutics
|
August 14, 2025
Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy
Gloria Aguilar, Gabriela Tapia-Calle, Cynthia Robinson, et al.
The Journal of Infectious Diseases
|
July 1, 2022
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign
Julien Nyombayire, Rosine Ingabire, Ben Magod, et al.
Trials
|
June 20, 2022
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial
Etienne Karita, Julien Nyombayire, Rosine Ingabire, et al.
The Lancet. Infectious Diseases
|
March 29, 2024
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial
Ynke Larivière, Trésor Zola Matuvanga, Bernard Isekah Osang'ir, et al.
The Journal of Infectious Diseases
|
September 6, 2023
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo
Ynke Larivière, Irene Garcia-Fogeda, Trésor Zola Matuvanga, et al.
Page
of 5